Handheld ECG Helps Physicians Identify Risks for Sudden Cardiac Arrest in Young Athletes

 

February 27, 2013
Cardea Associates CardeaScreen ECGs Point-of-Care Testing Athletes

Specifically in-tune with normal conditions for the athletic heart, the new CardeaScreen electrocardiographic (ECG) device is designed for use during pre-participation exams (PPE) for sports participants age 14 and older. This U.S. Food and Drug Administration (FDA)-cleared device helps physicians identify abnormal cardiac conditions that could lead to sudden cardiac arrest — at a much lower cost than other ECG systems currently on the market.

CardeaScreen is priced well below $3,000 to $10,000 — the price of most ECGs.

The handheld device wirelessly connects via Bluetooth to analysis software which runs on a standard user supplied Windows-based PC. The software allows physicians to input responses to specific PPE questions developed by the American Heart Association, as well as enter patient demographic information, previous symptoms of cardiac disease and Echocardiographic data when available. And because it is designed with the athlete in mind, CardeaScreen has a significantly lower rate of false positive results — false positives are a problem because they suggest that there is an abnormal heart condition when there is not. Such results are important to minimize since they could result in excluding an athlete from playing and lead to expensive medical evaluations.

CardeaScreen produces accurate, comprehensive results using quality data; the ECG transmitter digitizes at 1000 Hz and a resolution of 1 μVolt. The real-time recording screen continuously displays all ECG trace data that will be analyzed, helping the clinician correct patient motion and other noise that can degrade ECG quality. The single click of a button stops the recording and automatically analyzes the ECG, providing diagnostic recommendations for review by the physician.

The device implements recent diagnostic criteria developed in association with doctors at Stanford University, the University of Washington and other leading heart experts.

For more information: www.cardeascreen.com